• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.29% Nasdaq Down3.25%

    Pain Therapeutics Inc. (PTIE)

    1.74 Up 0.07(4.19%) 4:00PM EST
    ProfileGet Profile for:
    Pain Therapeutics Inc.
    7801 North Capital of Texas Highway
    Suite 260
    Austin, TX 78731
    United States - Map
    Phone: 512-501-2444
    Fax: 512-614-0414
    Website: http://www.paintrials.com

    Index Membership:N/A
    Full Time Employees:9

    Business Summary 

    Pain Therapeutics, Inc., a biopharmaceutical company, develops novel drugs in the United States. The company’s lead drug candidate is REMOXY, an extended-release oral formulation of oxycodone for the management of moderate-to-severe pain when a continuous and around-the-clock opioid analgesic is needed. It also develops abuse-resistant formulation of hydromorphone; and FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief. The company has strategic alliance with Pfizer, Inc. to develop and commercialize REMOXY. Pain Therapeutics, Inc. was founded in 1998 and is based in Austin, Texas.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Pain Therapeutics Inc.

    Corporate Governance 
    Pain Therapeutics Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Remi Barbier , 56
    Founder, Chairman, Chief Exec. Officer and Pres
    Mr. Peter S. Roddy , 56
    Chief Financial Officer, Principal Accounting Officer and VP
    Dr. Nadav Friedmann Ph.D., M.D., 73
    Chief Operating Officer, Chief Medical Officer and Director
    Mr. Michael J. O'Donnell Esq., 57
    Sec. and Director
    Mr. Michael Zamloot ,
    Sr. VP of Technical Operations
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders